0RU5 Stock Chart & Stats
kr86.60
-kr0.60(-0.69%)
At close: 4:00 PM EDT
kr86.60
-kr0.60(-0.69%)
Day’s Range― - ―
52-Week Rangekr40.20 - kr93.00
Previous CloseN/A
Volume6.00
Average Volume (3M)13.86K
Market Cap
kr408.43M
Enterprise Valuekr120.97
Total Cash (Recent Filing)kr140.16M
Total Debt (Recent Filing)kr818.00K
Price to Earnings (P/E)―
Beta0.40
Next Earnings
Oct 28, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.55
Shares Outstanding4,478,412
10 Day Avg. Volume9,044
30 Day Avg. Volume13,862
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical TrialsBerGenBio launches dual-inhibitor trial with first patient enrolled, focusing on patients with lung adenocarcinoma.
Safety DataPositive Phase 1b safety data support continued advancement of BGBC016 study.
Bears Say
Administrative DelaysThere have been some administrative delays in the trial, although management does not anticipate significant impacts on enrollment or the timeline.
Development ChallengesADC Therapeutics informed BerGenBio that the therapeutic window for ADCT-601 is too narrow, likely due to toxicities, impacting its development.
Oncoinvent ASA News
0RU5 FAQ
What was Oncoinvent ASA’s price range in the past 12 months?
Oncoinvent ASA lowest share price was kr40.20 and its highest was kr93.00 in the past 12 months.
What is Oncoinvent ASA’s market cap?
Oncoinvent ASA’s market cap is kr408.43M.
When is Oncoinvent ASA’s upcoming earnings report date?
Oncoinvent ASA’s upcoming earnings report date is Oct 28, 2026 which is in 60 days.
How were Oncoinvent ASA’s earnings last quarter?
Oncoinvent ASA released its earnings results on Aug 27, 2026. The company reported -kr15.2 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Oncoinvent ASA overvalued?
According to Wall Street analysts Oncoinvent ASA’s price is currently Overvalued.
Does Oncoinvent ASA pay dividends?
Oncoinvent ASA pays a Notavailable dividend of kr0.285 which represents an annual dividend yield of N/A. See more information on Oncoinvent ASA dividends here
What is Oncoinvent ASA’s EPS estimate?
Oncoinvent ASA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Oncoinvent ASA have?
Oncoinvent ASA has 4,478,412 shares outstanding.
What happened to Oncoinvent ASA’s price movement after its last earnings report?
Oncoinvent ASA reported an EPS of -kr15.2 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 8.899%.
Which hedge fund is a major shareholder of Oncoinvent ASA?
Currently, no hedge funds are holding shares in GB:0RU5
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Oncoinvent ASA
Oncoinvent ASA, a clinical-stage firm based in Oslo, Norway, is dedicated to developing innovative radiopharmaceutical treatments for various cancers. Its primary therapeutic agent is Radspherin, an alpha-emitting radiotherapeutic, which is currently undergoing investigation in two Phase 1/2a and one randomized Phase 2 clinical trials. This promising candidate is designed to target and treat malignancies that have metastasized to body cavities, specifically including the peritoneum.
Technical Analysis
Oncoinvent ASA
―
Bioxcel Therapeutics
―
Cellectar Biosciences
―
Fennec Pharmaceuticals
―
Geron
―
Kazia Therapeutics
―
Sorrento Therapeutics
―